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Abstract
Recent work identified L-asparaginase (L-ASP) as a putative therapeutic target for ovarian cancer. We suggest that L-ASP, a dysregulator of gly-
cosylation, would interrupt the local microenvironment, affecting the ovarian cancer cell—endothelial cell interaction and thus angiogenesis
without cytotoxic effects. Ovarian cancer cell lines and human microvascular endothelial cells (HMVEC) were exposed to L-ASP at physiologi-
cally attainable concentrations and subjected to analyses of endothelial tube formation, invasion, adhesion and the assessment of sialylated pro-
teins involved in matrix-associated and heterotypic cell adhesion. Marked reduction in HMVEC tube formation in vitro, HMVEC and ovarian
cancer cell invasion, and heterotypic cell-cell and cell-matrix adhesion was observed (P < 0.05–0.0001). These effects were associated with
reduced binding to ß1integrin, activation of FAK, and cell surface sialyl LewisX (sLex) expression. No reduction in HMVEC E-selectin expression
was seen consistent with the unidirectional inhibitory actions observed. L-ASP concentrations were non-toxic to either ovarian cancer or
HMVEC lines in the time frame of the assays. However, early changes of autophagy were observed in both cell types with induction of ATG12,
beclin-1, and cleavage of LC-3, indicating cell injury did occur. These data and the known mechanism of action of L-ASP on glycosylation of
nascent proteins suggest that L-ASP reduces of ovarian cancer dissemination and progression through modification of its microenvironment.
The reduction of ovarian cancer cell surface sLex inhibits interaction with HMVEC and thus HMVEC differentiation into tubes, inhibits interaction
with the local matrix reducing invasive behaviour, and causes cell injury initiating autophagy in tumour and vascular cells.
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Introduction
Tumour neovascularization and invasion are early and obligate events
dependent upon expression of cell surface glycoproteins and glyco-
conjugates [1–4]. Sialyl LewisX (sLex) is a tetrasaccharide carbohy-
drate that is often linked to cell-surface glycoproteins. Sialic acids in
general are overexpressed in some tumour cell types and play impor-
tant roles in biological characteristics of cancer and other cells that
are implicated in cellular invasiveness, differentiation and tumouri-
genecity [5–7]. L-asparaginase (L-ASP) has been reported to prevent
several forms of glycosylation, including sialylation, of newly synthe-
sized proteins [8–10].
The antimetabolic activity of L-ASP against acute lymphocytic leu-
kaemia (ALL) has been related to degradation and loss of the essen-
tial amino acid, asparagine, in this rapidly growing and highly
bioactive cancer [8, 10, 11]. The lower metabolic activity and slower
proliferation rate of ovarian cancers compared with ALL argues
against an essential amino acid-based anti-metabolic activity. Lorenzi
et al. demonstrated L-ASP inhibited growth of some epithelial ovarian
cancer cell lines and correlated growth inhibition with–omics findings
implicating low expression of the enzyme asparagine synthetase
(ASNS), that breaks down L-ASP, in a fraction of ovarian cancer
patients [12, 13]. That activity was due to protection of the L-ASP.
We reasoned that the altered glycosylation events caused by L-ASP
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would cause some of the injurious effects of L-ASP and examined
effects on invasive and cell- and matrix- interactions of ovarian cancer
cells.
Sialyl Lex is a major E-selectin ligand, mediating both homotypic
and heterotypic cell adhesion of endothelial cells [14–16]. Endothe-
lial cell surface E-selectin was shown to be necessary for endothe-
lial cell (EC) binding to colon cancer cells [14]. Its presence on the
surface of ECs is at least partly responsible for their morphogene-
sis into capillary-like tubes in vitro [16]. Interactions between the
tumour cell and the ECM play an equally important role in the initi-
ation of angiogenesis and invasion, and to support survival [14, 17
–19]. These interactions are primarily activated by integrins, a
family of heavily glycosylated cell surface proteins [20, 21]. Integrin
activation signals through critical survival and invasion pathways
that are mediated by focal adhesion kinase (FAK) [19, 22–24].
Inhibition of integrin binding and function results in decreased
angiogenic and invasive properties of cancer cells and loss of
matrix-independent growth, a process called anoikis [25, 26].
Numerous studies indicate that N-linked glycosylation expression
patterns of integrins are crucial to their ability to recognize
extracellular matrix proteins and thus support these cellular events
[27–30].
Attempts to use L-ASP in the treatment of solid malignancies
were made in the 1970’s without remarkable effect. Advances in solid
tumour management have led to improved patient clinical status and
allowed reconsideration of older drugs that may have useful mecha-
nisms of action. Ovarian cancer has a unique vulnerability to agents
that target signalling between the tumour and its local environment
[31–33] and is thus an ideal model system in which to evaluate the
ability of L-ASP to alter the tumour microenvironment. We suggest
that by altering the expression of cell-surface glycoproteins and gly-
coconjugates, L-ASP will significantly alter the interactions between
microvascular ECs, ovarian cancer cells, and ECM components,
resulting also in ovarian cancer cell injury.
Materials and methods
Materials
The VEGF165 was from R&D (Minneapolis, MN, USA). Matrigel and Bio-
coat Matrigel invasion chambers were purchased from BD Biosciences
(Bedford, MA, USA). XTT reagent was from Roche (Indianapolis, IN,
USA). Zymogram and immunoblot gels were from Invitrogen (Minneap-
olis, MN, USA). L-ASP and all other materials were reagent or molecular
grade. DMSO 0.1% was the vehicle control in all experiments.
Cells and viability
Several ovarian cancer cell lines were used to evaluate the potential
generalizability of the findings. Human ovarian cancer cell lines were
obtained from the ATCC (Manassas, VA, USA) and HEYA8 cells were
a gift of Dr. G. Mills (MD Anderson Cancer Center, Houston, TX,
USA; all were validated within 6 months of use). They were main-
tained in RPMI-1640 medium supplemented with 5% or 10% foetal
bovine serum and no more than 15% loss of viability was observed
in each of the cell lines with concentrations up to 3 U/ml and con-
tinuous exposure duration up to 24 hrs. Primary human microvascu-
lar endothelial cells (HMVECs), growth medium [Medium 131 with
5% microvascular cell growth supplement (MVGS)] and attachment
factor were purchased from Invitrogen/Cascade Biologics; HMVECs
were used between passages 3–6. Viability was measured with the
XTT assay and the L-ASP IC50 was 37 U/ml with a continuous expo-
sure of 6 days. Clinically targeted circulating L-ASP concentrations
are in the range of 0.3–3 U/ml and constituted the treatment range
used.
Capillary-like tube formation assay
Capillary tube formation was performed in vitro on Matrigel [34] in the
presence or absence of L-ASP over an 18–24 hrs period. High power
fields were digitized at 20X magnification, and total tube length (lm)
from four equal random areas per chamber was measured. A conver-
sion factor of 0.62 lm per pixel was applied (Nikon Imagine Software
BR 2.3; Nikon, Melville, NY, USA).
Invasion assay
The HMVECs were plated with or without L-ASP in growth medium
supplemented with 5% MVGS and 50 ng/ml VEGF165 for 16 hrs. Cells
were harvested, then subjected to invasion using serum-free medium
with VEGF165 50 ng/ml with or without 5%MVGS as attractant.
Serum-containing medium was used for ovarian cancer cell invasion.
Filters were fixed, stained and invaded cells in four random micros-
copy fields were counted with correction for spontaneous background
invasion.
Zymography
Zymography was performed as described using conditioned medium
from HT1080 cells as the control [35]. HMVECs were pre-treated with
L-ASP for 20 hrs then conditioned in MVGS-free medium containing L-
ASP for 24 hrs. Quantity was assessed over replicate gels using Image
Quant v5.2 (Molecular Dynamics, Sunnyvale, CA, USA).
Adhesion assays
Cell adhesion to defined matrices or antibodies examined cell-matrix
interactions. Adhesion molecule (2 lg/ml) or antibody (2 lg/ml) were
pre-bound on 96-well high binding plates (CoStar, Corning, Big Flats,
NY, USA) at 37°C for 60 min., then blocked with 0.1% fatty acid-free
BSA in PBS for 60 min. HEYA8 or HMVEC cells were pre-treated with
L-ASP and incubated for 60 min. Heterotypic cell adhesion was per-
formed as described by [14, 36]. Either tumour cells or HMVECs were
pre-treated with L-ASP or VEGF165 in growth medium for 16 hrs prior
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to fixation [14, 36]. In both assays, non-adherent cells were washed off
gently with PBS and adherent cells stained and quantified by XTT
assay.
Immunofluorescence and flow cytometry
Cells were grown on cover slips and treated with L-ASP, then washed
and fixed, permeabilized (for IF) and stained [37]. The cytoskeleton
was visualized by incubation with rhodamine-phalloidin (Invitrogen,
Carlsbad, CA, USA). Cells were counterstained with DAPI (Vector labo-
ratories, Burlingame, CA, USA) and fluorescence examined using a Ze-
iss LSM 510 confocal microscope (Carl Zeiss Inc, Thornwood, NY,
USA) using a Nikon Plan Apo 609/1.4 oil immersion objective. In
some cases, a series of Z-plane optical sections were taken through
the depth of the cells with a thickness of 1 lm at intervals of
0.2 lm. Expression of cell surface protein in non-permeabilized cells
was assessed by flow cytometry according to manufacturer’s protocol
(Cell Signaling, Danvers, MA, USA). Paraformaldehyde (1%) -fixed
cells were incubated with anti-sialyl Lewisx (sCD15) or E-selectin
(1:50; Calbiochem, San Diego, CA, USA) and visualized with Alexa
488-conjugated secondary antibodies (1:200; ThermoScientific, Rock-
ford, IL, USA) by FACS Calibur flow analysis (BD Biosciences, San
Jose, CA, USA). Data were analysed using FlowJo (TreeStar Inc, Palo
Alto, CA, USA).
Immunoblot
Cell lysates were prepared with modified RIPA lysis buffer and sub-
jected to immunoprecipitation and immunoblotting [37]. Lysates
underwent no more than one freeze/thaw cycle. All antibodies were
from Cell Signaling with the exception of LC-3 (Novus Biologicals,
Redmond, WA, USA) and anti-phospho-FAK (Tyr397; Millipore, Billeri-
ca, MA, USA).
Statistical approaches
Unless otherwise indicated, unpaired Student’s t-test was used to exam-
ine statistical relationships against vehicle control. Results are presented
as mean ± S.E.M. of at least three replicate experiments, including gels,
unless otherwise specified.
Results
L-ASP inhibits in vitro capillary tube formation
and vascular remodelling
Vascular tube formation is approximated experimentally using an in vitro
Matrigel substratum assay [34]. The concentrations and time of expo-
sures used for these and all other experiments were outside the L-ASP
toxicity range as described in Methods. L-ASP pre-exposed HMVECs
were plated onto a Matrigel-coated chamber in the presence of L-ASP.
Untreated HMVECs formed well organized tube-like structures (Fig. 1A).
L-ASP 0.3 U/ml, a clinically attainable concentration, resulted in a
marked reduction in the number and complexity of tube structures.
Greater attenuation was observed at higher concentrations. The average
summated length of capillary tubes was significantly reduced with L-ASP
incubation (P  0.005; Fig. 1B), indicating that L-ASP inhibits morpho-
genesis of endothelial cells into capillary-like tubes.
L-ASP inhibits invasion of both, but differentially
inhibits attachment, of HMVEC and ovarian
cancer cells
Inhibition of invasive behaviour of microvascular
endothelial cells
Normal vessel remodelling is one of the several examples of physio-
logical invasion [17]. Thus, we examined inhibition of HMVEC inva-
sion by L-ASP. A statistically significant reduction in number of
invaded HMVEC cells was observed in a dose-dependent fashion
(P = 0.004; Fig. 2A). Breakdown of extracellular matrix by MMP-2
promotes physiologic invasion and capillary remodelling of ECs. The
quantity and activity of MMP-2 in HMVEC conditioned medium was
markedly reduced with increased dose of L-ASP (P < 0.0001; zymo-
gram inset; Fig. 2B).
L-ASP inhibits ovarian cancer invasion
The concentrations and time of exposures used for all ovarian cancer
cell experiments were outside the L-ASP toxicity range. L-ASP was
A B
Fig. 1 L-ASP inhibits tube formation on Matrigel. L-ASP exposure inhibited HMVEC differentiation into tubes in vitro in a dose dependent fashion.
(A) Representative fields. (B) Cumulative tube length in 4HPF/well for replicate experiments (*P < 0.001, ** P < 0.005).
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maintained during invasion towards the serum-containing medium
chemoattractant. Invasion was significantly decreased in all ovarian
cancer cell lines (P  0.05, P-values were determined on experi-
mental raw data; Fig. 2C). Thus, L-ASP inhibits both physiological
invasion of vascular remodelling and malignant invasion of the ovar-
ian cancer cells.
L-ASP inhibits ß1 integrin-mediated cell-ECM attachment
and signalling
The invasiveness of ECs and tumour cells is regulated by interac-
tion with the ECM through integrins, where the ß1subunit is most
common. The ß1subunit has been shown to require glycosylation
for activity [29, 30]. HMVEC and HEYA8 cells pre-treated with
L-ASP were allowed to bind to substratum coated with laminin,
fibronectin and collagen IV. No reduction in HMVEC adhesion to
ECM proteins was observed; in contrast, adhesion of HEYA8 cells
to laminin and fibronectin was strongly inhibited by L-ASP, with lit-
tle effect on binding to collagen IV (P  0.0002; Fig. 2D, left).
Consistent with this, defective adhesion was observed when L-ASP
treated-HEYA8 cells were incubated on an anti-ß1 integrin antibody
substratum (P = 0.02), with no significant change in HMVEC adhe-
sion (Fig. 2D, right). Total integrin ß1 on the surface of all cells
was unchanged over all concentrations of L-ASP tested (Fig. 2E).
A
C
D
E
B
Fig. 2 L-ASP inhibits invasion and causes differential matrix-attachment of HMVEC and ovarian cancer cells at physiologically attainable concentra-
tions. (A) Dose-dependent inhibition of HMVEC invasion. HMVEC cells treated with and continuously exposed to L-ASP were subjected to invasion
towards VEGF165 in complete medium; P  0.004. (B) L-ASP inhibits HMVEC MMP2 quantity and activity. HMVEC serum-free CM was collected
and examined by zymography (quantified replicate zymograms, S.E.M., P  0.0001; inset, representative gel). (C) L-ASP inhibits invasion of ovar-
ian cancer cells. Ovarian cancer cells treated with and continuously exposed to L-ASP were subjected to invasion towards serum. Replicate experi-
ments and S.E.M. are presented. HEYA8, P  0.04; CAOV3, P  0.05; SKOV3, P  0.01. (D) Dose-dependent inhibition of HEYA8 but not
HMVEC attachment to ECM glycoproteins. Pretreated cells were allowed to attach to indicated substratum proteins (left panel: HEYA8, dashed lines,
P  0.0002; HMVEC cells, solid lines) or to a lawn of anti-ß1 integrin antibody (right panel, HEYA8 cells P = 0.02). (E) L-ASP exposure does not
change expression of ß1-integrin in either cell type, shown by immunoblot.
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Thus, L-ASP may alter ß1-integrin conformation or surface oligo-
saccharide differentially on the ovarian cancer cells, resulting in
altered adhesion.
L-ASP alters FAK activation and stress fibre
organization
Integrin-ECM interactions result in activation of FAK via autophospho-
rylation at 397Y [38]. L-ASP exposure reduced p397Y-FAK in both cell
types without affecting total FAK (Fig. 3A). The lack of change in
quantity of HMVEC ß1-integrin suggests that dysregulation of FAK
may be due to other effects of L-ASP. Focal adhesions are the out-
side-in integrin-mediated signalling bodies that stimulate formation of
actin stress fibres. Immunofluorescence imaging of HEYA8 cells con-
firmed reduced matrix-cell signalling by showing reduction in p397Y-
FAK-labelled focal adhesions (Fig. 3B). L-ASP reduced number and
thickness of the actin stress fibres in HMVEC cells. Stress fibres were
reduced in quantity and associated with a change in actin organization
and cell shape in the HEYA8 ovarian cancer cells (Fig. 3C, top and
bottom respectively); the effect on the ovarian cancer cells shape and
size and degree of stress fibres appears stronger. These results sug-
gest that L-ASP may selectively modify extracellular ß1-integrin in
ovarian cancer cells over HMVEC causing inhibition of integrin
engagement, and reduced adhesion to matrix and altered actin reor-
ganization.
Inhibition of heterotypic adhesion of ovarian
cancer cells to ECs
Cells receive survival signals via ECM- and cell-cell mediated attach-
ment. Heterotypic cell-cell adhesion is an early step in tumour dis-
semination and has been shown to involve glyco- and sialyl-proteins
[4, 25]. We therefore asked if L-ASP effects extended to cell-cell
adhesion. L-ASP treated ovarian cancer cells had reduced adhesion to
an untreated, fixed (non-viable) HMVEC monolayer. Reduction in het-
erotypic cell adhesion occurred only when tumour cells were exposed
to L-ASP (Fig. 4A,B; P < 0.01–0.05). No effect of L-ASP treatment of
HMVEC was seen whether treated HMVEC cells were immobilized and
fixed for tumour cell adhesion (Fig. 4B, triangles) or applied viably to
immobilized, fixed ovarian cancer cells (HEYA8, Fig. 4B squares;
SKOV3, CAOV3 cells, Fig. 4C; P  0.01). SKOV3 and CAOV3 cells
were examined up to 1 U/ml to corroborate the effects of the HEYA8
and to avoid broaching toxic concentrations. These data indicate that
L-ASP alters cell-cell adhesion in a unidirectional fashion, implicating
alteration of a key cell surface component of the ovarian cancer cells
required for attachment to HMVECs.
A
B
C
Fig. 3 L-ASP alters FAK activation and stress
fibre organization. (A) L-ASP exposure
reduces p397Y-FAK. The dose-dependent
reduction is less in HMVEC (left panel)
than in HEYA8 cells (right). (B) Dose
dependent reduction in HEYA8 focal adhe-
sions labelled by p397Y-FAK immunofluo-
rescence. The quantity and organization of
focal adhesions is reduced in HEYA8 cells.
(C) L-ASP treatment inhibits actin stress
fibre formation in HMVEC and HEYA8
cells. HMVEC cells have reduction in
quantity and thickness of stress fibres
(arrows), whereas there is both a reduc-
tion in stress fibers (arrows) and reorga-
nization of actin (arrowheads) in the
HEYA8 cells.
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Cell surface sLex is reduced by L-ASP treatment
Sialylation of Lex is a common regulatory event required for morpho-
genesis of ECs into capillary tubes, activation of ß1 integrin and for
heterotypic cell-endothelial cell binding [16, 29, 39]. L-ASP treatment
significantly reduced surface sLex expression in HMVEC and HEYA8
cells measured by flow cytometry (Fig. 5A; P  0.02 and <0.002
respectively). Reduced surface sLex was associated with decreased
binding of treated HEYA8 cells to the anti-sLex substratum (Fig. 5B;
P  0.01), but not of treated HMVEC cells. The dichotomous behav-
iour with a dose dependent change in binding to sLex, but a stable
reduction in quantity of sLex is a consistent observation. sLex on the
surface of solid tumour cells serves as a major ligand for E-selectin
on ECs [14, 36]. L-ASP did not alter the ability of HMVEC to bind to
an anti-E-selectin substratum (Fig. 5C, left panel); likewise, we found
no alteration in HMVEC cell surface E-selectin quantity (Fig. 5C, right
panel). The L-ASP mediated reduction in HMVEC surface sLex did not
alter their E-selectin adhesive function. Thus, L-ASP inhibition of sLex
expression on ovarian cancer cells unilaterally inhibits binding to
sialylated integrin or HMVEC cell surface E-selectin.
Induction of autophagy by L-ASP
The L-ASP inhibits glycosylation-associated events necessary for
ovarian cancer survival and dissemination at concentrations and
durations that did not cause cell death. However, it has been shown
previously to inhibit ovarian cancer proliferation [12, 13]. Autophagy
is a mechanism through which the cell attempts to protect itself from
injury and death by shutting down its environmental interactions and
using its internal resources for survival but may remain functional [40
–42]. Exposure to L-ASP for 16 hrs caused no reduction in mitochon-
drial respiration by XTT assay (Fig. 1) but did activate autophagy
pathways both in the presence (Fig. 6) or absence of serum (not
shown). L-ASP concentrations only up to 1 U/ml were used to mini-
mize transition from autophagy to apoptosis. Induction of AMPK,
ATG12, beclin-1 and/or cleavage of LC3 occurred at physiologically
attainable L-ASP concentrations (0.3–1 U/ml) in two ovarian cancer
cell lines and the primary culture HMVEC cells; similar beclin
induction results were observed in CAOV3 cells as well. These results
A
B C
Fig. 4 Heterotypic adhesion of tumour cells
to HMVEC cells is reduced by L-ASP treat-
ment. Treated HEYA8 cells are unable to
bind to a monolayer of HMVEC cells in a
dose-dependent fashion. (A) Representa-
tive adhesion fields. (B) Quantification
showing only treatment of HEYA8 cells
results in inhibition of heterotypic binding
(dotted line; 0.3 U/ml, P < 0.05; 1.0 U/ml,
P < 0.01; 3 U/ml, P < 0.006). (C) Similar
loss of heterotypic adhesion is seen with
treatment of CAOV3 (P  0.001) and
SKOV3 (P  0.01) ovarian cancer cells.
C
A
B
Fig. 5 L-ASP alters surface sLex expression and sLex-requiring
responses. (A) Reduction in sLex expression, mean ± S.E.M. S.E.M.
(HMVEC, P < 0.02; HEYA8, P < 0.002). (B) L-ASP exposed HMVEC
were not and HEYA8 cells were inhibited in a dose-dependent fashion in
binding to a lawn of anti- sLex. (1 dot, P = 0.02; 2 dots, P  0.01; 3
dots, P  0.001). (C) L-ASP does not affect E-selectin. Pretreated
HMVEC cells have no reduction in their binding to immobilized anti-E-
selectin (left panel) nor is their expressed E-selectin affected (right
panel).
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indicate that both microvascular cells and ovarian cancer cells are
susceptible to potential L-ASP-associated injury during conditions
where there is reduction in invasive and angiogenic activity.
Discussion
Focal genetic driving events have not been identified for the bulk of
high-grade serous ovarian cancers TCGA [43]; thus, successful inter-
vention requires a broader look at the cellular and molecular events
involved in supporting and sustaining its growth and dissemination.
We and others have demonstrated a close link between angiogenesis
and ovarian cancer at the correlative, prognostic, predictive and clini-
cal levels and numerous clinical trials have examined the role of
angiogenesis as a molecular target in ovarian cancer [31, 32]. Active
vascularization has been confirmed to be an important molecular tar-
get in the tumour microenvironment of ovarian cancer, requiring cell-
cell and cell-matrix interactions for success [17]. We have sought
new clinically translatable mechanisms with which to modulate angio-
genesis in ovarian cancer.
Many agents studied and applied early in the anti-neoplastic era
were examined selectively in a leukaemia background. Some, such
as L-ASP, went on to be successful anti-leukemic agents and had
no or little additional examination in solid tumours after limited ini-
tial success. The role of asparaginase in ALL has been attributed to
its anti-metabolic activity, essentially removing adequate amounts
of the necessary amino acid, asparagine, required for the rapid
growth, metabolism and protein glycosylation in ALL cells [8, 10].
It was proposed early on that an important mechanism of action of
L-ASP is the inhibition of de novo production of asparaginyl-N-gly-
coproteins at the post-Golgi level [8, 9]. CD15, a cell-surface gly-
can consisting of the Gal-ß(1–4)-(Fuc-a(1–3))-GlcNAc trisaccharide,
is differentially recognized when sialylated [44, 45]. Sialyl-CD15
(sCD15) recognizes the sLex epitopes that bind E-selectin and facili-
tate heterotypic cell adhesion. CD15 sialylation and sialidase activity
regulating CD15 expression on human myeloid cells was shown to
regulate their differentiation [44]. It is thus possible that L-ASP
may promote myeloid differentiation during leukaemia therapy by
inhibition of sLex. Likewise, the reduction in HMVEC differentiation
activity in our in vitro models in response to L-ASP exposure may
be a function of interruption of sLex/E-selectin differentiation signal-
ling.
Asparagine synthetase, the enzyme responsible for synthesis of
asparaginase, may be differentially expressed in tumour cells contrib-
uting to poor L-ASP activity. Low expression of ASNS was identified
in ovarian cancer cell lines in which an inverse response between
ASNS quantity and susceptibility to L-ASP was demonstrated [12,
13]. We suggest that the functional activities of L-ASP would relate to
its anti-metabolic/glycosyl regulatory activities. Reduction of
glycosylation-associated activation events should and did reduce
angiogenesis and invasive behaviour. This would lead to a locally
non-permissive microenvironmental cancer milieu while not altering
the normal physiology. Our findings confirming this provide an argu-
ment for clinical examination of L-ASP in ovarian cancer.
A
BFig. 6 L-ASP induces autophagy in HMVEC
and ovarian cancer cells. Exposure to L-
ASP in the presence of serum results in
induction of AMPK, ATG12, beclin-1, and
LC3 cleavage in OVCAR8, HEYA8, and
HMVEC cells. (A) Representative immuno-
blots. LC3 cleavage from LC3-I to LC3–II
is shown with arrows. (B) Quantification
of replicate immunoblots, mean ± S.E.M.,
one dot, P < 0.01; two dots, P  0.001.
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Both endothelial and ovarian cancer cells had an approximately 50%
reduction in surface sLex expression with L-ASP exposure. Only the
ovarian cancer cells were inhibited by L-ASP in binding to anti-sLex, indi-
cating a unidirectional process. The lack of reduction in HMVEC E-selec-
tin, the sLex ligand, further supports the one-sidedness of the finding
and suggests that L-ASP modulates the permissiveness of the tumour
microenvironment, a hypothesis that may apply also to ALL in the bone
marrow [11, 46]. The dichotomy between reduction in surface sLex and
the binding of the HEYA8 cells to it may be due to the quality and extent
of sialylation. A key enzyme in sialylation is b-galactoside a2,6-sialyl-
trans-ferase (ST6Gal-I). This enzyme has been shown to be upregulated
in ovarian cancer cells promoting invasiveness through sialylation of b1
integrin [39]. Similar increase in attachment to basement membrane col-
lagen IV was associated with ST6Gal-I enzyme activity in breast cancer
cells [47]. Tumours induced in MMTV-ST6Gal-I null mice have more
normal breast differentiation, decreased activation of FAK and when
genetically complemented, have restored ß1-integrin signalling [48]. Our
findings of reduction in functional ß1-integrin and inhibited binding to b1-
integrin in response to L-ASP are consistent with these mechanisms.
The lack of reduction in cell-cell attachment when the ECs were
exposed to L-ASP can be explained by the sidedness of glycosylation-
requiring adhesion events. ECs are activated in response to extracel-
lular matrix protein binding, growth factors and via E-selectin in het-
erotypic interactions with tumour cells [14, 16]. Each can result in
induction of motility, invasion and proliferation. E-selectin binding is
specific to LewisA/X-containing ligands [16]. VEGF165 is a glycosylated
isoform of the VEGF protein and is a critical stimulant of endothelium
that is produced by the tumour microenvironment, and most or all
ovarian cancer cells. Affinity and response to the different VEGF iso-
forms is different, with VEGF165 being one of the most potent. Altered
recognition of this glycosylated product may be another mechanism
through which L-ASP alters microenvironment activity. VEGF165 alone
is insufficient to induce and sustain HMVEC or HUVEC tube formation
on Matrigel in our hands (Kohn, unpublished data). L-ASP incubation
did not reduce VEGF production by the ovarian cancer cell lines, as
measured by specific ELISA using conditioned medium (not shown).
We showed that L-ASP reduced physiological and malignant inva-
sive events at concentrations and durations of exposure that were
non-toxic. This growth independence from sLex has also been
described in colon cancer cells where specifically selected high and
low sLex expressors were found to have the same proliferative capac-
ity but low sLex expression was associated with reduced invasion [7].
We then made two seminal observations: (1) adhesive behaviour was
unidirectional with the primary effects of L-ASP against the ovarian
cancer cells blocking adhesion to HMVEC cells and glycosylated
extracellular basement membrane proteins; and (2) L-ASP induced
autophagy in both HMVEC and ovarian cancer cells, where the earliest
signs were observed as early as 24 hrs. Loss of attachment is known
to induce apoptosis through anoikis [19] but this may be forestalled if
the cells enter autophagy first [49, 50]. Autophagy is a mechanism
through which cells rely on their internal resources to ride out a
storm, such as exposure to an anti-metabolite like L-ASP [40, 42,
51]. As expected, some variance in the degree of autophagy and con-
centration sensitivity was observed. Induction of autophagy concomi-
tantly with loss of invasive behaviour has been seen with many
targeted and anti-angiogenic agents [52, 53] and could explain the
lack of cytotoxicity we observed.
These findings elucidate a novel paradigm for L-ASP mechanism
of action. The reduction in sialylation needed for integrin activation
and engagement, and heterotypic cell-cell adhesion alters the balance
of interaction and cell signalling in the local tumour microenviron-
ment. Heterotypic adhesion of ovarian cancer cells also occurs to the
peritoneal mesothelium, facilitating shedding and subsequent dissem-
ination. This may occur in part through the mesothelin/CA125 interac-
tion, another glycosylated process [54]. This may be an adequate
single agent therapeutic in rapidly growing and angiogenesis-requir-
ing ALL. There may be therapeutic activity of L-ASP in the angiogenic
setting in solid tumours, although it may require combination therapy
to realize its full potential. The pegylated asparaginase, pegaspargase,
now in use provides an alternative intravenous formulation with which
to further examine L-ASP behaviour. A pilot phase II trial of pegas-
pargase in ovarian cancer is open in our institution (NCT01313078)
and includes translational angiogenesis and glycosylation endpoints
to illustrate this potential novel mechanism of action.
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